11/25/2009

The European Medicines Agency granted fast-track designation to Shire's velaglucerase alfa, a drug candidate for Gaucher disease. The company submitted the drug, which could address a shortage of Genzyme's Cerezyme, to the FDA in September.

Full Story:
Reuters

Related Summaries